[Burden of disease and level of patient's medical care in substitution treatment for opiates]
- PMID: 20039157
- DOI: 10.1007/s00063-009-1196-2
[Burden of disease and level of patient's medical care in substitution treatment for opiates]
Abstract
Background and purpose: Within the framework of an interdisciplinary cooperation, the authors set up an on-site medical service provider in a specialized methadone substitution center in Germany. Here, they report on the prevalence of infectious and noninfectious diseases, and the vaccination status of substituted heroin-dependent patients.
Patients and methods: All patients who visited the medical care service provider between February 2008 and December 2008 were included in this study.
Results: Ten patients (7%) were seropositive for the hepatitis A virus. Two patients (1.3%) suffered from chronic hepatitis B; 40 patients (27%) were cured after a hepatitis B infection. Additionally, 99 patients (68%) were infected with hepatitis C virus (HCV), and 41 patients (28%) had active hepatitis C. Furthermore, 48 hepatitis C patients (33%) were cured. Of those, 25 patients (17%) cleared the virus spontaneously and 23 (16%) after ribavirin/interferon combination therapy. Ten (7%) of 146 patients were infected with the human immunodeficiency virus (HIV). Of those, four patients had active hepatitis C, and five patients were cured after a hepatitis C infection. 18 patients (12%) were vaccinated against hepatitis A and 28 (19%) against hepatitis B. Two of the 41 patients with chronic hepatitis C were vaccinated against hepatitis A. The most frequent noninfectious diagnoses were arterial hypertension (n = 28), bronchial asthma (n = 8), and diffuse liver parenchymal damage (n = 12).
Conclusion: These results emphasize that i.v. drug users on substitution therapy are an underserved collective with a high prevalence of disease. The challenge consists in facilitating this population access to internistic and infectious disease service. The offer of an on-site medical service was well accepted. This is essential for an ongoing reduction of HIV and HCV prevalence in the drug users.
Similar articles
-
Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.Eur J Gen Pract. 2007;13(1):5-12. doi: 10.1080/14017430601049365. Eur J Gen Pract. 2007. PMID: 17366287
-
Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study.J Addict Dis. 2010 Jul;29(3):359-69. doi: 10.1080/10550887.2010.489449. J Addict Dis. 2010. PMID: 20635285 Free PMC article.
-
Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.N Z Med J. 2001 Jul 27;114(1136):324-6. N Z Med J. 2001. PMID: 11548096
-
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).Int J Drug Policy. 2007 Aug;18(4):262-70. doi: 10.1016/j.drugpo.2006.12.014. Epub 2007 Jan 26. Int J Drug Policy. 2007. PMID: 17689374 Review.
-
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.Curr Drug Abuse Rev. 2008 Jun;1(2):177-87. doi: 10.2174/1874473710801020177. Curr Drug Abuse Rev. 2008. PMID: 19630716 Review.
Cited by
-
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.PLoS One. 2014 Jul 28;9(7):e103345. doi: 10.1371/journal.pone.0103345. eCollection 2014. PLoS One. 2014. PMID: 25068274 Free PMC article.
-
Hepatitis B vaccination coverage in Germany: systematic review.BMC Infect Dis. 2021 Aug 14;21(1):817. doi: 10.1186/s12879-021-06400-4. BMC Infect Dis. 2021. PMID: 34391406 Free PMC article.
-
The epidemiology of Hepatitis B, C and D in Germany: A scoping review.PLoS One. 2020 Mar 9;15(3):e0229166. doi: 10.1371/journal.pone.0229166. eCollection 2020. PLoS One. 2020. PMID: 32150561 Free PMC article.
-
Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study.Eur J Health Econ. 2013 Oct;14(5):799-808. doi: 10.1007/s10198-012-0425-4. Epub 2012 Sep 19. Eur J Health Econ. 2013. PMID: 22990377
-
Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.Front Public Health. 2020 Aug 28;8:424. doi: 10.3389/fpubh.2020.00424. eCollection 2020. Front Public Health. 2020. PMID: 33014960 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical